Consolidating 4 register for dating sites scam

Fit out is expected to begin later this month, with a target completion date at year’s end.Cambrex expanded into Edinburgh when it acquired Avista.

consolidating 4-2

While the concept of the one-stop-shop is attractive, the question is whether the big CDMOs can or will offer the value and capabilities across the different service offerings that emerging biotech companies need (i.e., they may be competitive for some development services and on the high end for other services).” For Cambrex, the planned acquisition by Permira caps a year in which it expanded operations beyond small-molecule and generic drug substance manufacturing, entering the finished dosage form CDMO segment by purchasing Halo Pharma last year for approximately $425 million.

Cambrex also added comprehensive early-stage and analytical testing services, plus early-stage development capabilities for both advanced pharmaceutical ingredients (APIs) and finished dosage forms, by snapping up Avista Pharma Solutions for about $252 million in a deal completed January 2.

According to Permira’s website, its healthcare group has made 13 investments totaling €1.5 billion (about $1.7 billion) in equity in biotech, heavy medical equipment, hospitals, and veterinary medicine companies with a combined €1.1 billion ($1.2 billion) in sales.

“We look forward to partnering with Cambrex’s talented management and employees to support the growth of its integrated services offering,” Minello added.

The Avista deal brought Cambrex “a broad funnel of over 200 new customers for whom they work on hundreds of molecules,” Klosk told analysts on the company’s quarterly conference call February 13, according to a transcript published by .

Cambrex acquired both companies from investment firms: Avista from Ampersand Capital Partners, and Halo from SK Capital Partners.In addition to its headquarters, Cambrex operates North American facilities in Whippany, NJ; Charles City, IA; High Point and Durham, NC; Longmont, CO; Agawam, MA; and Mirabel, QC, Canada.The company’s European facilities are located in Karlskoga, Sweden; Paullo, Milan, Italy; Tallinn, Estonia; Wiesbaden, Germany; and Edinburgh, Scotland.In addition, Cambrex said, it can support conventional dosage forms including oral solids, semi-solids, and liquids and can manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile, and non-sterile ointments.“Over many years, Cambrex has built a leading position with best-in-class capabilities and facilities, backed by an excellent reputation for quality and technical expertise,” added Henry Minello, principal in the global healthcare group of Permira.[Cambrex]Cambrex said today it has agreed to be acquired by an affiliate of the global investment firm Permira for approximately .4 billion, in a deal the company said will position it for further growth in the consolidating contract development and manufacturing organization (CDMO) sector.

Tags: , ,